vs
CytomX Therapeutics, Inc.（CTMX）与FIRST US BANCSHARES, INC.（FUSB）财务数据对比。点击上方公司名可切换其他公司
CytomX Therapeutics, Inc.的季度营收约是FIRST US BANCSHARES, INC.的1.8倍（$18.7M vs $10.4M），FIRST US BANCSHARES, INC.净利率更高（20.4% vs -0.8%，领先21.3%），FIRST US BANCSHARES, INC.同比增速更快（7.1% vs -25.7%），FIRST US BANCSHARES, INC.自由现金流更多（$9.1M vs $-15.8M），过去两年FIRST US BANCSHARES, INC.的营收复合增速更高（2.6% vs -15.9%）
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
第一美国银行控股公司是一家银行控股企业，核心子公司第一公民银行在美国23个州经营着超过500家网点，另一家子公司硅谷银行则在15个州设有39个办事处，是美国规模较大的银行机构之一，总部位于北卡罗来纳州罗利。
CTMX vs FUSB — 直观对比
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $10.4M |
| 净利润 | $-154.0K | $2.1M |
| 毛利率 | — | — |
| 营业利润率 | -6.9% | 28.1% |
| 净利率 | -0.8% | 20.4% |
| 营收同比 | -25.7% | 7.1% |
| 净利润同比 | 97.6% | 24.2% |
| 每股收益（稀释后） | — | $0.36 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | — | $10.4M | ||
| Q3 25 | — | $10.5M | ||
| Q2 25 | $18.7M | $10.3M | ||
| Q1 25 | $50.9M | $9.8M | ||
| Q4 24 | $38.1M | $9.7M | ||
| Q3 24 | $33.4M | $10.1M | ||
| Q2 24 | $25.1M | $10.0M | ||
| Q1 24 | $41.5M | $9.9M |
| Q4 25 | — | $2.1M | ||
| Q3 25 | — | $1.9M | ||
| Q2 25 | $-154.0K | $155.0K | ||
| Q1 25 | $23.5M | $1.8M | ||
| Q4 24 | $18.9M | $1.7M | ||
| Q3 24 | $5.7M | $2.2M | ||
| Q2 24 | $-6.5M | $2.1M | ||
| Q1 24 | $13.8M | $2.1M |
| Q4 25 | — | 28.1% | ||
| Q3 25 | — | 23.9% | ||
| Q2 25 | -6.9% | 1.6% | ||
| Q1 25 | 44.4% | 23.8% | ||
| Q4 24 | 46.4% | 23.8% | ||
| Q3 24 | 12.3% | 29.2% | ||
| Q2 24 | -33.7% | 27.4% | ||
| Q1 24 | 28.1% | 27.8% |
| Q4 25 | — | 20.4% | ||
| Q3 25 | — | 18.4% | ||
| Q2 25 | -0.8% | 1.5% | ||
| Q1 25 | 46.2% | 18.1% | ||
| Q4 24 | 49.6% | 17.6% | ||
| Q3 24 | 17.2% | 22.0% | ||
| Q2 24 | -26.0% | 21.2% | ||
| Q1 24 | 33.3% | 21.3% |
| Q4 25 | — | $0.36 | ||
| Q3 25 | — | $0.32 | ||
| Q2 25 | — | $0.03 | ||
| Q1 25 | — | $0.29 | ||
| Q4 24 | — | $0.29 | ||
| Q3 24 | — | $0.36 | ||
| Q2 24 | — | $0.34 | ||
| Q1 24 | — | $0.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.0M | $73.5M |
| 总债务越低越好 | — | $10.9M |
| 股东权益账面价值 | $119.9M | $105.6M |
| 总资产 | $175.1M | $1.2B |
| 负债/权益比越低杠杆越低 | — | 0.10× |
8季度趋势，按日历期对齐
| Q4 25 | — | $73.5M | ||
| Q3 25 | — | $54.7M | ||
| Q2 25 | $49.0M | $54.0M | ||
| Q1 25 | $47.6M | $56.0M | ||
| Q4 24 | $38.1M | $47.2M | ||
| Q3 24 | $40.6M | $82.3M | ||
| Q2 24 | $43.2M | $58.2M | ||
| Q1 24 | $36.2M | $60.2M |
| Q4 25 | — | $10.9M | ||
| Q3 25 | — | $10.9M | ||
| Q2 25 | — | $10.9M | ||
| Q1 25 | — | $10.9M | ||
| Q4 24 | — | $10.9M | ||
| Q3 24 | — | $10.9M | ||
| Q2 24 | — | $10.8M | ||
| Q1 24 | — | $10.8M |
| Q4 25 | — | $105.6M | ||
| Q3 25 | — | $104.2M | ||
| Q2 25 | $119.9M | $101.9M | ||
| Q1 25 | $25.0M | $101.2M | ||
| Q4 24 | $-456.0K | $98.6M | ||
| Q3 24 | $-23.5M | $98.5M | ||
| Q2 24 | $-31.2M | $93.8M | ||
| Q1 24 | $-31.7M | $92.3M |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | $175.1M | $1.1B | ||
| Q1 25 | $98.5M | $1.1B | ||
| Q4 24 | $120.5M | $1.1B | ||
| Q3 24 | $139.0M | $1.1B | ||
| Q2 24 | $159.2M | $1.1B | ||
| Q1 24 | $184.7M | $1.1B |
| Q4 25 | — | 0.10× | ||
| Q3 25 | — | 0.10× | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | — | 0.11× | ||
| Q4 24 | — | 0.11× | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.12× | ||
| Q1 24 | — | 0.12× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.8M | $12.3M |
| 自由现金流经营现金流 - 资本支出 | $-15.8M | $9.1M |
| 自由现金流率自由现金流/营收 | -84.6% | 87.2% |
| 资本支出强度资本支出/营收 | 0.1% | 31.1% |
| 现金转化率经营现金流/净利润 | — | 5.79× |
| 过去12个月自由现金流最近4个季度 | $-77.7M | $16.0M |
8季度趋势，按日历期对齐
| Q4 25 | — | $12.3M | ||
| Q3 25 | — | $4.2M | ||
| Q2 25 | $-15.8M | $3.9M | ||
| Q1 25 | $-21.0M | $1.8M | ||
| Q4 24 | $-19.9M | $7.8M | ||
| Q3 24 | $-20.7M | $1.9M | ||
| Q2 24 | $-19.5M | $2.5M | ||
| Q1 24 | $-26.0M | $825.0K |
| Q4 25 | — | $9.1M | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | $-15.8M | $1.6M | ||
| Q1 25 | $-21.2M | $1.7M | ||
| Q4 24 | $-20.0M | $5.7M | ||
| Q3 24 | $-20.7M | $1.3M | ||
| Q2 24 | $-19.6M | $2.3M | ||
| Q1 24 | $-26.2M | $-142.0K |
| Q4 25 | — | 87.2% | ||
| Q3 25 | — | 34.2% | ||
| Q2 25 | -84.6% | 16.0% | ||
| Q1 25 | -41.6% | 17.2% | ||
| Q4 24 | -52.5% | 58.2% | ||
| Q3 24 | -62.1% | 12.7% | ||
| Q2 24 | -78.2% | 23.5% | ||
| Q1 24 | -63.1% | -1.4% |
| Q4 25 | — | 31.1% | ||
| Q3 25 | — | 5.9% | ||
| Q2 25 | 0.1% | 21.8% | ||
| Q1 25 | 0.2% | 0.7% | ||
| Q4 24 | 0.2% | 21.6% | ||
| Q3 24 | 0.1% | 6.6% | ||
| Q2 24 | 0.4% | 2.0% | ||
| Q1 24 | 0.3% | 9.8% |
| Q4 25 | — | 5.79× | ||
| Q3 25 | — | 2.18× | ||
| Q2 25 | — | 25.16× | ||
| Q1 25 | -0.89× | 0.99× | ||
| Q4 24 | -1.05× | 4.53× | ||
| Q3 24 | -3.61× | 0.87× | ||
| Q2 24 | — | 1.20× | ||
| Q1 24 | -1.89× | 0.39× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
FUSB
暂无分部数据
